Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged BYL
If Hatch-Waxman cases are governed by TC Heartland, will that lead to “generic friendly” districts?

Mylan ($MYL) recently prevailed on a motion to dismiss for improper venue in a pending Hatch-Waxman case for the drug Eliquis®.  Mylan successfully argued that Delaware was an improper venue under the recently test for venue in patent cases enunciated by the Supreme Court in TC Heartland.  What are the implications of TC Heartland governing venue in all Hatch-Waxman cases?  Will it lead to “generic friendly” judicial districts?

Read More
Markman AdvisorsMylan, Bristol-Meyers Squibb, MYL, $MYL, $BYL, BYL, $BMY, BMY, TC Heartland, venue, Hatch-Waxman, generic, brand, generic drug, Federal Circuit, Eliquis, Zachary Silbersher, SilbersherComment